OSUR icon

OraSure Technologies

3.65 USD
-0.07
1.88%
At close Jan 17, 4:00 PM EST
After hours
3.61
-0.04
1.10%
1 day
-1.88%
5 days
1.39%
1 month
-5.68%
3 months
-10.32%
6 months
-17.98%
Year to date
3.11%
1 year
-55.10%
5 years
-55.60%
10 years
-63.32%
 

About: OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.

Employees: 638

0
Funds holding %
of 6,823 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

5% less capital invested

Capital invested by funds: $301M [Q2] → $287M (-$13.8M) [Q3]

8% less call options, than puts

Call options by funds: $22K | Put options by funds: $24K

5.34% less ownership

Funds ownership: 95.53% [Q2] → 90.2% (-5.34%) [Q3]

11% less funds holding

Funds holding: 210 [Q2] → 187 (-23) [Q3]

20% less repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 70

45% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 49

Research analyst outlook

We haven’t received any recent analyst ratings for OSUR.

Financial journalist opinion

Based on 7 articles about OSUR published over the past 30 days

Positive
Zacks Investment Research
4 days ago
New Strong Buy Stocks for January 16th
MRCY, BBCP, OSUR, VIK and IFS have been added to the Zacks Rank #1 (Strong Buy) List on January 16, 2025.
New Strong Buy Stocks for January 16th
Neutral
Business Wire
1 week ago
NOWDiagnostics Responds with Countersuit Against Frivolous OraSure Claims
SPRINGDALE, Ark.--(BUSINESS WIRE)--NOWDiagnostics, Inc. (NOWDx), a leader in developing over-the-counter (OTC) and point-of-care (POC) diagnostic tests, filed a claim on Jan. 13 against OraSure Technologies (OraSure), asserting breach of contract, theft of a non-public device, misappropriation of trade secrets, unfair competition, and other violations of state and federal law for damages in federal court in the Eastern District of Pennsylvania. NOWDx is seeking compensatory and punitive damages.
NOWDiagnostics Responds with Countersuit Against Frivolous OraSure Claims
Neutral
GlobeNewsWire
1 week ago
OraSure to Present at the J.P Morgan Healthcare Conference
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. OraSure's presentation is scheduled for Thursday, January 16, 2025 at 9:00 a.m. PT.
OraSure to Present at the J.P Morgan Healthcare Conference
Positive
Zacks Investment Research
1 week ago
Are Investors Undervaluing OraSure Technologies (OSUR) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing OraSure Technologies (OSUR) Right Now?
Neutral
GlobeNewsWire
1 week ago
CORRECTION - OraQuick® HIV Self-Test Now Approved for Use in Adolescents
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Tuesday, January 7th by OraSure Technologies, Inc. (NASDAQ: OSUR), please note that the first sentence of the release (read "OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents.") is incomplete. The corrected release follows:
CORRECTION - OraQuick® HIV Self-Test Now Approved for Use in Adolescents
Neutral
GlobeNewsWire
1 week ago
OraQuick® HIV Self-Test Now Approved for Use in Adolescents
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick® HIV Self-Test. Previously the test was approved for use in those 17 and older.
OraQuick® HIV Self-Test Now Approved for Use in Adolescents
Positive
Zacks Investment Research
3 weeks ago
OSUR Stock Rises Following the Acquisition of Sherlock Biosciences
OraSure announces acquisition of Sherlock Biosciences to strengthen its molecular diagnostics portfolio.
OSUR Stock Rises Following the Acquisition of Sherlock Biosciences
Neutral
GlobeNewsWire
1 month ago
OraSure Technologies Acquires Sherlock Biosciences
BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers.
OraSure Technologies Acquires Sherlock Biosciences
Positive
Seeking Alpha
1 month ago
OraSure Technologies: Discounted Assets With An Attractive Free Call Option
OraSure Technologies is undervalued, trading below its net current asset value, offering a compelling risk-reward scenario with limited downside risk. The company has a robust balance sheet with no long-term debt and $280 million in cash, mitigating downside risks. Post-COVID margins are expected to improve, driving positive cash flow and substantial upside potential, with a projected 70%+ appreciation.
OraSure Technologies: Discounted Assets With An Attractive Free Call Option
Neutral
GlobeNewsWire
1 month ago
OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test
BETHLEHEM, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test
Charts implemented using Lightweight Charts™